Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States

KingMillion25 Mar. 17 at 10:44 AM

$NVCT Q2 data incoming

0 · Reply

LawrenceStevenson1996 Mar. 10 at 5:32 PM

$NVCT Small cap health. Quiet session.

0 · Reply

biospeculator Mar. 10 at 4:12 PM

$NVCT Massive inverse head & shoulders pattern building with a $11 neckline and a target of $18-$20 imo. GLTA

0 · Reply

Elgallo353 Mar. 10 at 3:43 PM

$NVCT why the increase ? any other forum where there is more info ? this is so quiet…

1 · Reply

UNLV Feb. 27 at 2:27 PM

$NVCT phase 1b moving forward and SecForm4 shows ZERO insider selling. Charles Mosseri Marlio doesn’t work for Nuvectis and isn’t strictly bound by insider trading rules. Piggybacked his huge buys around friendship with CEO unless and until he starts selling have to believe positives around 1b @BioTrade2 and there’s nothing better than getting in huge at ground floor

1 · Reply

StocktwitsEarnings Feb. 25 at 3:30 PM

$NVCT Q4 '25 Earnings Results & Recap Nuvectis Pharma reported a net loss of $(26,442) thousand and basic net loss per share of $(1.32) for FY2025, with $31,634 thousand in cash. Nuvectis Pharma ceased NXP800 development and initiated NXP900 Phase 1b expansion in 2025.

0 · Reply

OfficialStocktwitsUser Feb. 22 at 7:05 PM

$NVCT RSI: 58.37, MACD: 0.1273 Vol: 0.23, MA20: 8.60, MA50: 8.26 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 18 at 4:21 PM

$NVCT Current Stock Price: $8.91 Contracts to trade: $7.5 NVCT Feb 20 2026 Call Entry: $0.35 Exit: $0.60 ROI: 72% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

UNLV Feb. 17 at 6:28 PM

$NVCT IMO upcoming data around the big target of tagrisso resistance will propel stock price setting up a “FREE-ROLL on ALL other indications”. Keeping patients on tagrisso an additional 6 months or longer would be welcomed by medical professionals and catapult company to profitability

0 · Reply

cupcakes4jesus Feb. 13 at 1:18 PM

$NVCT so grateful to be able to buy this stock at $8-9. Will be life changing. Biotrade2 is blocked. Ignore the noise and negativity

0 · Reply

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Dec 17, 2025, 7:00 AM EST - 3 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nov 25, 2025, 8:00 AM EST - 4 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 4, 2025, 8:15 AM EST - 4 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 16, 2025, 8:00 AM EDT - 5 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 4, 2025, 7:30 AM EDT - 6 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:30 PM EDT - 7 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 5, 2025, 7:30 AM EDT - 8 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 31, 2025, 7:45 AM EDT - 8 months ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

May 16, 2025, 4:35 PM EDT - 10 months ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 11 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 11 months ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 1 year ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 1 year ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 1 year ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 3 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 3 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

KingMillion25 Mar. 17 at 10:44 AM

$NVCT Q2 data incoming

0 · Reply

LawrenceStevenson1996 Mar. 10 at 5:32 PM

$NVCT Small cap health. Quiet session.

0 · Reply

biospeculator Mar. 10 at 4:12 PM

$NVCT Massive inverse head & shoulders pattern building with a $11 neckline and a target of $18-$20 imo. GLTA

0 · Reply

Elgallo353 Mar. 10 at 3:43 PM

$NVCT why the increase ? any other forum where there is more info ? this is so quiet…

1 · Reply

UNLV Feb. 27 at 2:27 PM

1 · Reply

StocktwitsEarnings Feb. 25 at 3:30 PM

0 · Reply

OfficialStocktwitsUser Feb. 22 at 7:05 PM

0 · Reply

BillionerOfKing Feb. 18 at 4:21 PM

0 · Reply

UNLV Feb. 17 at 6:28 PM

0 · Reply

cupcakes4jesus Feb. 13 at 1:18 PM

$NVCT so grateful to be able to buy this stock at $8-9. Will be life changing. Biotrade2 is blocked. Ignore the noise and negativity

0 · Reply

cupcakes4jesus Feb. 13 at 1:32 AM

$NVCT this will be $100 by end of year

1 · Reply

d_risk Feb. 11 at 11:33 PM

$NVCT - Nuvectis Pharma Inc - 10K - Updated Risk Factors NVCT’s 2026 10-K sharpens its early-stage, cash-needs and commercialization risk narrative, adds new exposure to tariffs and U.S. agency funding disruptions, reshuffles clinical and COVID-related trial risks around NXP900, and deepens emphasis on complex global regulatory, pricing, and reimbursement hurdles. #Biopharmaceuticals #TariffExposure #FundingDisruptions #RegulatoryRisks #ClinicalTrials 🟢 Added 🟠 Removed https://dev.d-risk.ai/NVCT/10-K/2026-02-11

0 · Reply

buyandsold Feb. 11 at 4:41 PM

$NVCT dip in for the 10x If you are a baby dip in for a quick hitter 10%

0 · Reply

WallStWireAds Feb. 11 at 12:32 PM

$NVCT https://caplynx.io/6cD8EVt

0 · Reply

WallStWireAds Feb. 10 at 10:13 PM

$SLXN $VSTM $HALO $NVCT

0 · Reply

WallStWireAds Feb. 8 at 3:31 PM

$SLXN $VSTM $HALO $NVCT After Big Pharma Validated KRAS, an Under the Radar Microcap Is Approaching Human Trials in Pancreatic Cancer >> https://thefinanceherald.com/after-big-pharma-validated-kras-an-under-the-radar-microcap-is-approaching-human-trials-in-pancreatic-cancer/

0 · Reply

UNLV Feb. 5 at 4:46 PM

$NVCT crypto crashing and AI plunging let me remind again NVCT has heavy insider buying and huge insider ownership. Nuvectis Pharma a SLAM DUNK backed by huge bullish indicator

0 · Reply

BioTrade2 Jan. 30 at 8:39 PM

$NVCT 50K block. Someone wanted out quick.

1 · Reply

kkorotney Jan. 28 at 3:27 PM

$NVCT this stock is going to make or break me. Excited for 2026.

0 · Reply

BioTrade2 Jan. 28 at 11:27 AM

$NVCT short Interest rising again. They drove the price down last time https://www.nasdaq.com/market-activity/stocks/nvct/short-interest

2 · Reply

OfficialStocktwitsUser Jan. 23 at 7:20 PM

$NVCT RSI: 49.85, MACD: 0.3246 Vol: 0.43, MA20: 8.26, MA50: 7.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

WallStWireAds Jan. 21 at 12:33 PM

$NVCT

0 · Reply

Market Cap	239.22M
Revenue (ttm)	0.00
Net Income (ttm)	-26.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	68,200
Avg Vol	62,270
Day's Range	N/A - N/A
Shares Out	26.49M
Stochastic %K	5%
Beta	-0.31
Analysts	Strong Sell
Price Target	$18.00